

# WARFARIN & OTHER ORAL ANTICOAGULANTS GUIDELINES AND PROCEDURES

This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances of the individual patient in consultation with the patient and /or carer. Health care professionals must be prepared to justify any deviation from this guidance.

## Introduction

Anticoagulants are one of the classes of medicines most frequently identified as causing preventable harm and admission to hospital. Managing the risks associated with anticoagulants can reduce the chance of patients being harmed. This Trust Guideline is based on British Committee for Standards in Haematology (BCSH) and National Patient Safety Agency (NPSA) guidance

### THIS GUIDELINE IS FOR USE BY THE FOLLOWING STAFF GROUPS:

All staff caring for or managing patients on anticoagulant therapy must have the necessary Trust adapted NPSA work competences/procedures included in this document ([See Part 2.](#))

### Lead Clinician

Dr David Davies	Consultant Haematologist
Keith Hinton	Clinical Team Lead Pharmacist
Mohima Akhtar	Lead Pharmacist for Stroke & Thrombosis
Approved by Haematology Governance	19 <sup>th</sup> March 2025
Approved by Medicines Safety Committee on:	14 <sup>th</sup> August 2024
Review Date:	19 <sup>th</sup> March 2028
This is the most current document and should be used until a revised version is in place	

### Key amendments to this guideline

Date	Amendment	By:
April 2012	Expiry extended to July 2012 whilst under review	M Crowther
June 2012	Major changes to the Guideline. Warfarin indications re-written based on latest BCSH guidelines, warfarin management and reversal re-written based on new oral anticoagulant prescription charts and section on rivaroxaban and dabigatran included for the first time.	M Crowther
November 2012	Addition of more prescribing information for dabigatran and rivaroxaban and prescriber and patient information sheets	M Crowther

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

December 2012	Bridging therapy tables re-written to be more clear	M Crowther E Maughan
August 2013	Major re-write to include new oral anticoagulants	M Crowther
November 2015	Major re-write to include information of new oral anticoagulants and APC guidance on single agent. Part	M Crowther

	1 is entirely new while Part 2 remains unchanged.	
December 2017	Addition of edoxaban as a treatment option for cancer associated thrombosis	K Hinton
December 2017	Sentence added in at the request of the Coroner	
May 2020	Additional advice to take rivaroxaban with food Updated indication for edoxaban Advice not to use DOACs in patients with antiphospholipid syndrome Changes to recommendations in cancer / body weight Reference to Peri-operative oral anticoagulant bridging. WAHT-KD-017. Advice to check renal function prior to initiating DOACs Fax numbers changed to email addresses. Appendix B (interactions) removed in favour of using an up to date online resource.	K Hinton
July 2020	Addition of statement 'Edoxaban should be prescribed as first line DOAC in the treatment of non-valvular AF' following MPC decision. Addition of HAE-002A as appendix	K Hinton
December 2020	Minor changes to explicit dosing for DOACs in renal impairment as per licenses and changing GFR to CrCr	K Hinton/M Hallissey
June 2024	Minor grammatical changes, use of CrCl throughout document, half-life updated from renal drug database, clarification of data in tables 1 and 2, cost of tablets updated, apixaban as first line choice of DOAC for AF added (correct as of June 2024), guideline for apixaban or rivaroxaban reversal with andexanet alfa attached, guideline for management of venous thromboembolism attached, correction to medication names in Appendix C, replacement of HAS-BLED tool with ORBIT tool.	Mohima Akhtar

## Contents

---

Introduction .....	1
Key amendments to this guideline .....	1
Part 1 – Clinical Guideline .....	6
Introduction .....	6
Conversion between the drugs.....	7
Monitoring on DOACs .....	7
Pharmacology.....	8
Indications and choosing the most appropriate drug.....	9
Prophylaxis of venous thromboembolism (VTE) following elective hip or knee replacement surgery.....	9
Atrial fibrillation .....	10
Decision to anticoagulate .....	10
Choice of anticoagulants in patients newly diagnosed with atrial fibrillation.....	10
Doses of DOACs in atrial fibrillation.....	12
Newly diagnosed patients .....	13
Patients already established on warfarin .....	14
Cardioversion.....	14
Acute coronary syndrome .....	14
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).....	15
Choice of anticoagulation for treatment of suspected or confirmed DVT/PE.....	15
Flowchart for choosing anticoagulation in DVT/PE.....	16
Patients with DVT/PE already established on warfarin.....	17
Doses of DOACs in DVT/PE.....	19
Management of patients on oral anticoagulants going for procedures which require interruption of anticoagulation .....	20

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

Elective procedures .....	20
High risk of thrombosis.....	20
Low risk of thrombosis .....	20
Warfarin .....	20

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

Dabigatran .....	20
Apixaban.....	20
Edoxaban .....	21
Rivaroxaban.....	21
Minor procedures.....	21
Protocol for managing anticoagulants when operation cancelled following temporary cessation of oral anticoagulants .....	21
Urgent procedures .....	22
High risk of thrombosis.....	22
Low risk of thrombosis .....	22
Warfarin .....	22
DOACs – Dabigatran, Apixaban, Edoxaban or Rivaroxaban.....	23
Dabigatran.....	23
Management of patients on oral anticoagulants who are bleeding.....	24
High risk of thrombosis .....	24
Low risk of thrombosis .....	24
Warfarin.....	25
DOACs.....	25
Patient taking dabigatran attends with a major life, limb or sight threatening bleed....	26
Overdosage of oral anticoagulants.....	27
Warfarin.....	27
DOACs .....	27
Dabigatran .....	27
Apixaban .....	27
Rivaroxaban or Edoxaban.....	27
Management of low INRs.....	28
Atrial fibrillation .....	28

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

Mechanical heart valves .....	28
Treatment of DVT/PE.....	29
Inpatient warfarin management.....	30
Prescription charts .....	30
Initiation of Warfarin .....	30
Warfarin maintenance .....	31
Drugs interacting with warfarin .....	31
Discharge arrangements.....	32
Information for Patients.....	33
 Part 2 – In-Patient Anticoagulation With Oral Anticoagulants In WAHT -Responsibilities Of Each Profession.....	 34
Procedures/Competences.....	37
Initiating oral anticoagulant therapy – Authorised Prescribers.....	37
MAINTAINING ORAL ANTICOAGULANT THERAPY .....	39
DISPENSING ORAL ANTICOAGULANTS.....	40
ADMINISTERING (AND DISCHARGING PATIENTS ON) ORAL ANTICOAGULANTS.....	41
 Appendix A - Conversion between the drugs .....	 43
Appendix B – Atrial fibrillation risk calculators .....	47
CHA <sub>2</sub> DS <sub>2</sub> -VASC Score.....	47
ORBIT tool .....	49
 Appendix C - Prescribing-Omission of Oral Anticoagulation for Endoscopy.....	 51
 CONTRIBUTION LIST.....	 52
Supporting Document 1 - Equality Impact Assessment Tool .....	53
Supporting Document 2 – Financial Impact Assessment.....	60

## Part 1 – Clinical Guideline

### Introduction

There are three classes of oral anticoagulants available to prescribers in Worcestershire:

- Vitamin K antagonists – warfarin, phenindione and acenocoumarol
- Anti-Xa agents – apixaban, rivaroxaban and edoxaban
- Direct thrombin inhibitors – dabigatran

Traditionally warfarin has been the anticoagulant of choice for several indications. Warfarin has the advantages of:

- It has a wide range of indications
- Its effect can easily be measured
- It can be reversed immediately and simply
- It has very few side-effects, apart from bleeding
- It can be used in severe renal failure
- Cost of tablets is cheaper than alternatives
- Its long half-life means missing a dose has a lower

clinical impact

However its disadvantages are:

- It requires regular monitoring and dose adjustments
- It has multiple drug interactions
- Its effect is impacted by diet, age and exercise

There are now four direct oral anticoagulant drugs (DOAC) licensed and NICE approved for use in certain indications. These have the advantages over warfarin of:

- Having a single dose
- Having fewer drug interactions
- There is no requirement for regular monitoring or dose adjustments
- There may be an improvement in outcomes and reduction in bleeding when compared to warfarin

They do have disadvantages:

- They are all in part renally excreted
- They have fewer licensed indications compared to warfarin
- There is minimal long term safety data
- Their short half-life means missing a dose leads to the patient being un-anticoagulated
- Patients with antiphospholipid syndrome
  - DOACs are not recommended for patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome. In particular, for patients that are triple positive (for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies). Treatment with DOACs could be associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

Therefore the decision on whether a patient should receive warfarin or a DOAC should involve a careful appraisal of the risk/benefit for each drug and a detailed discussion between the patient, the prescriber and wider MDT.

## **Conversion between the drugs**

It is relatively easy to convert between the oral anticoagulants (and low molecular weight heparin). For detailed guidance see appendix A.

## **Monitoring on DOACs**

Patients on a DOAC should have their renal and liver function measured prior to initiation and annually if they are normal and six monthly if abnormal, taking note at what level these drugs can no longer be prescribed.



## Pharmacology

	Warfarin	Dabigatran	Apixaban	Rivaroxaban	Edoxaban
<b>Class</b>	Vitamin K antagonist ( the synthesis of factor II, VII, IX and X and proteins C and S)	Direct anti-thrombin inhibitor	Anti-Xa inhibitor	Anti-Xa inhibitor	Anti-Xa inhibitor
<b>Bioavailability</b>	>95%	6.5%	>50%	>80% with food	62%
<b>Tmax (Time to reach peak drug concentration)</b>	Variable but requires alternative anticoagulant until INR therapeutic for 2 days if immediate anticoagulation is required	2 hours	3-4 hours	2-4 hours	1-2 hours
<b>Half-life (data from renal drug database)</b>	35-45 hours	12-17 hours	12 hours	7-11 hours	10-14 hours
<b>Renal clearance</b>	0%	85% ( <b>contra-indicated if CrCl&lt;30ml/min</b> , consider dose reduction to 110mg BD in those patient with CrCl 30-50mls/min and increased bleeding risk)	27% ( <b>contra-indicated if CrCl&lt;15ml/min</b> , use with caution 15-30mls/min, for atrial fibrillation dose reduce to 2.5mg BD in patients with creatinine >133mmol/L)	36% ( <b>contra-indicated if CrCl&lt;15mls/min</b> , use with caution 15-30mls/min with dose reduction to 15mg OD for AF)	35% ( <b>contra-indicated if CrCl&lt;15mls/min</b> , use with caution 15-50mls/min with dose reduction to 30mg OD)
<b>Protein binding</b>	99%	35%	87%	>90%	10-59%
<b>Drug interactions (see eBNF for full details)</b>	Multiple - any drug that affects the CYP2C9, 3A4, 1A2 enzymes*, alcohol or things that affect vitamin K (antibiotics and foods)	P-gp inhibitors*	Potent CYP3A4 inhibitors*  P-gp inhibitors*	Potent CYP3A4 inhibitors*  P-gp inhibitors*	Potent CYP3A4 inhibitors*  P-gp inhibitors*
<b>Monitoring of anticoagulant effect</b>	INR	Has some effect on the APTT, if prolonged patient likely to be anticoagulated, if normal cannot exclude residual anticoagulant activity.	Prolongs clotting tests such as PR, INR and APTT but these are not recommended to assess anticoagulant effect of apixaban. Also reduced factor Xa.	Has some effect on the PT, if prolonged patient likely to be anticoagulated, if normal cannot exclude residual anticoagulant activity.	Has a linear effect on both the PT and APTT but interpretation unclear.
<b>Licensed</b>	Multiple indications	AF VTE prevention following hip or knee replacement Treatment of VTE Prophylaxis of recurrent VTE	AF VTE prevention following hip or knee replacement Treatment of VTE Prophylaxis of recurrent VTE	AF ACS PAD VTE prevention following hip or knee replacement Treatment of VTE Prophylaxis of recurrent VTE	AF Treatment of VTE Prophylaxis of recurrent VTE
<b>Daily cost (BNF)</b>	£0.03-0.18 per day but does not include cost of monitoring. NHS average of £25 per INR clinic visit.	£1.82 per day	£0.18 per day for generic apixaban  <b>Apixaban is now first line option for AF</b>	£1.80 per day	£1.75 per day

Table 1: Pharmacology of enoxaparin and DOACs

\*see eBNF for comprehensive interactions. Sources used for this table include BNF monographs, renal drug database data as well as summary of product characteristics for each medication.

## Indications and choosing the most appropriate drug

### Prophylaxis of venous thromboembolism (VTE) following elective hip or knee replacement surgery.

The National Institute for Health and Care Excellence (NICE) recommends pharmacological VTE prophylaxis for 28-35 days following a hip replacement and 10-14 days following a knee replacement.

Drug	Dose	Duration	VTE events compared to LMWH	Bleeding events compared to LMWH
Enoxaparin	40mg OD (20mg with CrCl<30mls/min or <50kg) 12 hours before surgery then daily	Hip 28-35 days  Knee 10-14 days	Treatment with LMWH gives rate of 0.8%	Treatment with LMWH gives rate of 4%
Dabigatran	110mg 1-4 hours after surgery then 220mg OD starting the following day (75mg 1-4 hours after surgery then 150mg OD starting the following day for those with CrCl 30-50ml/min, those taking p-gp inhibitors such as amiodatone and those over 75 years).	Hip 28-35 days  Knee 10 days	No difference	No difference
Apixaban	2.5mg BD starting 12-24 hours after surgery	Hip 32-38 days  Knee 10-14 days	No difference	3.8% versus 4.7% (lower risk vs enoxaparin)  NNT 112
Rivaroxaban	10mg OD with food starting 6-10 hours after surgery	Hip 5 weeks  Knee 2 weeks	0.5% versus 1% (lower risk vs enoxaparin)  NNT 182	4.5% versus 3.5% (higher risk vs enoxaparin)  NNH 106

*Table 2: Doses of enoxaparin vs DOACs for VTE prophylaxis following hip or knee replacement surgery. Also compares VTE risk of enoxaparin vs DOACs and bleeding events (Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012;344:e3675)*

NNT – number needed to treat

NNH – number needed to harm

Currently in Worcestershire the preferred method of thromboprophylaxis is with Enoxaparin.

## Atrial fibrillation

### Decision to anticoagulate

NICE guidance NG196 states that all patients with atrial fibrillation are assessed for their stroke risk using the CHA<sub>2</sub>DS<sub>2</sub>-VASC scoring system (Appendix B) if they have:

- symptomatic or asymptomatic paroxysmal, persistent or permanent atrial fibrillation
- atrial flutter
- a continuing risk of arrhythmia recurrence after cardioversion back to sinus rhythm

or catheter ablation

Dependent on the score the following is recommended:

Score	0	1	≥2
Men	No anticoagulation	Consider anticoagulation	Offer anticoagulation
Women	No anticoagulation	No anticoagulation	Offer anticoagulation

For those patients in whom anticoagulation is being considered or offered, an ORBIT score (appendix B) should be performed to determine the bleeding risk on anticoagulation. The bleeding risk and the stroke risk should be compared and a discussion with the patient held to determine a preference for anticoagulation. NICE do not recommend withholding anticoagulation because of a risk or history of falls, as the chance of suffering a major bleed because of a fall is low.

NICE approved on-line calculators:

- CHA<sub>2</sub>DS<sub>2</sub>-VASC <http://www.mdcalc.com/cha2ds2-vasc-score-for-atrial-fibrillation-stroke-risk/#how-to-use>
- ORBIT [ORBIT Bleeding Risk Score for Atrial Fibrillation \(mdcalc.com\)](http://www.mdcalc.com/orbit-bleeding-risk-score-for-atrial-fibrillation/)

Patients should be regularly re-assessed (yearly and after a major clinical event) to determine if risks have changed and whether they still require/ don't require anticoagulation.

### Choice of anticoagulants in patients newly diagnosed with atrial fibrillation

The five oral anticoagulants that are licensed (warfarin, dabigatran, apixaban, edoxaban and rivaroxaban) for prevention of stroke and systemic emboli in atrial fibrillation have slightly different licensing indications dependent on risk factors being present:

Risk factor (can be prescribed if present)	Apixaban	Dabigatran	Edoxaban	Rivaroxaban	Warfarin
Valvular AF (mitral stenosis or prosthetic mitral valve)					✓
Previous stroke, TIA or systemic emboli	✓	✓	✓	✓	✓
LV ejection fraction below 40%	✓	✓	✓	✓	✓
Symptomatic heart failure NYHA class or above	✓	✓	✓	✓	✓
Age 75 years or older	✓	✓	✓	✓	✓
Hypertension	✓	✓	✓	✓	✓
Diabetes mellitus	✓	✓	✓	✓	✓

Table 3: Risk factors that can be present for use of each DOAC and warfarin

There is no evidence or trial that compares the DOACs directly and the patient population and study outcomes are slightly different therefore true comparisons are difficult. It does appear however that there is a trend towards improved outcomes and reduced bleeding with the DOACs.

Edoxaban is the DOAC of choice for non-valvular AF as it is the DOAC that is the lowest acquisition cost to the health economy as per NICE guidelines.

**Warfarin remains essential for:**

- Metallic heart valve
- Moderate or severe mitral stenosis/valvular AF
- Severe renal dysfunction (CrCl <15 mL)
- LV thrombus (unless otherwise directed by patient's cardiologist)
- In patients who have a history of antiphospholipid syndrome

There is an absence of robust clinical data to support definitive prescribing recommendations of DOACs in patients with BMI > 40 kg/m<sup>2</sup> or >120 kg total body weight. Above these parameters, it remains unclear whether adequate drug concentrations are achieved to be clinically effective.

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

**Doses of DOACs in atrial fibrillation**

Drug	Patient factor	Dose
Dabigatran	Standard dose	150mg BD
	<ul style="list-style-type: none"> <li>Age &gt;80 years</li> <li>Taking verapamil</li> </ul>	110mg BD
	<ul style="list-style-type: none"> <li>Age 75-80 years</li> <li>Moderate renal impairment (CrCl 30-50ml/ml)</li> <li>Gastritis, oesophagitis or gastro-oesophageal reflux</li> <li>Increased risk of bleeding</li> </ul>	Consider reduction to 110mg BD
	CrCl<30ml/min	Contra-indicated
Apixaban	Standard dose	5mg BD
	Two of the following: <ul style="list-style-type: none"> <li>Age ≥80 years</li> <li>Weight ≤60kg</li> <li>Creatinine ≥133micromol/L OR CrCl 15-29ml/min</li> </ul>	2.5mg BD
	CrCl<15mls/min	Contra-indicated
Edoxaban	Standard dose	60mg OD
	Any of the following: <ul style="list-style-type: none"> <li>CrCl 15-50mls/min</li> <li>Weight ≤60kg</li> <li>Use of ciclosporin, dronedarone, erythromycin or ketoconazole</li> </ul>	30mg OD
	CrCl<15mls/min	Contra-indicated
Rivaroxaban	Standard	20mg OD
	If CrCl was 15-49mls/min	15mg OD
	CrCl <15mls/min	Contra-indicated

\*see eBNF monographs for full details

Table 4: Doses of DOACs in AF

### **Newly diagnosed patients**

The decision whether to start warfarin or a DOAC should involve a discussion between the prescriber and the patient. Given the ease of use of DOACs compared to warfarin it is likely that the patient would prefer a DOAC.

Patient likely to benefit most from warfarin:

- Indication not covered by DOAC e.g. valvular AF
- Severe renal failure (CrCl<15mls/min except dabigatran which is <30mls/min) or high chance of significant deterioration
- Hepatic dysfunction
- Prosthetic (metal or tissue) heart valves
- Arterial grafts
- Patient concerns over long term safety data
- Taking other drugs where DOACs are contra-indicated (refer to eBNF)
- Other medical conditions where data on the use of DOACs is limited
- Use of unusual drugs where experience of them alongside DOACs is limited
- Target INR other than 2.5 (2.0-3.0) as DOACs designed to give equivalent anticoagulation to INR 2.5
- Obesity (body weight >120 kg) – very limited data for this patient group with DOACs
- Concerns regarding patient compliance where ability to easily monitor anticoagulation effect is desirable.


Patient likely to benefit most from DOAC:

- Regularly prescribed drugs that interferes with warfarin e.g. COPD patient with multiple courses of antibiotics
- Difficulty attending INR clinics (personal or medical reasons)

Likely poor compliance is not a reason for choosing a DOAC, the relative short half-life means missed doses leaves the patients without anticoagulation until the next dose is taken, the relative long half-life of warfarin means an occasional missed dose is unlikely to affect the INR.

### Patients already established on warfarin

Patients on warfarin for atrial fibrillation should be given the option of changing to a DOAC. Patients should be assessed using the following flow-chart.



The reasons for choosing a DOAC or warfarin is discussed above and should also be applied to patients already on warfarin. Changing from warfarin to a DOAC is discussed in appendix A.

### Cardioversion

A common reason for the cancellation of a cardioversion is a sub-therapeutic INR. The use of a DOAC prior and after the procedure should prevent this.

Although there is limited data with the DOAC drugs in the setting of DC cardioversion, all of them have some data and the local decision has been to proceed with cardioversion with any of the drugs. Patients will need to take the DOAC for a minimum of 3 weeks before and 1 month after cardioversion. Because the effect cannot easily be measured, patient compliance is crucial.

### Acute coronary syndrome

There is data regarding the use of apixaban and rivaroxaban in acute coronary syndromes, but using lower doses than used in AF. There is no data for the other agents. Patients with AF and an acute coronary syndrome, particularly if PCI has been performed, present a particular problem and decisions will be made by the cardiologist on an individual basis.

## Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)

### Choice of anticoagulation for treatment of suspected or confirmed DVT/PE

The options for anticoagulating patients with suspected (while awaiting imaging) or proven DVTs or PEs are:

1. LMWH (standard for care for pregnant patients)
2. LMWH then conversion to warfarin
3. LMWH then conversion to dabigatran
4. Apixaban
5. Rivaroxaban
6. LMWH then conversion to Edoxaban (especially for patients with cancer but avoid in patients with a high risk of bleeding, especially upper GI malignancies, given the increased risk of bleeding)

For in-depth detail please refer to Trust guideline WAHT-HAE-019: Guideline for the management of venous thromboembolism including the management of patients receiving low molecular weight heparin



Guideline for the  
Management of Ven



## WAHT-HAE-002

It is the responsibility of every individual to check that this is the latest version/copy of this document

For those patients who are to be considered for a DOAC a discussion between the patient and the prescriber is required. A patient information leaflet is available.

Patient likely to benefit most from warfarin:

- Indication not covered by DOAC e.g. valvular AF, prosthetic valves
- Severe renal failure (CrCl<30mls/min) or high chance of significant deterioration
- Hepatic dysfunction
- Arterial grafts
- Patient concerns over longterm safety data
- Taking other drugs where DOACs are contra-indicated (seen appendix B)
- Other medical conditions where data on the use of DOACs is limited
- Use of unusual drugs where experience of them alongside DOACs is limited
- Obesity (body weight >150 kg) – very limited data for this patient group with DOACs
- Patient choice
- Concerns regarding patient compliance where ability to easily monitor anticoagulation effect is desirable.

There may be more benefit to treatment of DVT/PE with a DOAC compared to AF as the majority of patients are treated for a short period of time, therefore longterm side-effects are less of a problem. Also the highest risk of bleeding on warfarin is in the first three months and that is when the majority of blood tests are.

Patient likely to benefit most from DOAC:

- Regularly prescribed drugs that interferes with warfarin e.g. COPD patient with multiple courses of antibiotics
- Difficulty attending INR clinics (personal or medical reasons)

Likely poor compliance is not a reason for choosing a DOAC, the relative short half-life means missed doses leaves the patients without anticoagulation until the next dose is taken, the relative long half-life of warfarin means an occasional missed dose is unlikely to affect the INR.

**Doses of DOACs in DVT/PE**

Drug	Patient factor	Dose
Dabigatran	Standard dose	Five days of treatment dose LMWH (which is 1mg/kg BD) followed by 150mg BD dabigatran
	<ul style="list-style-type: none"> <li>Age &gt;80 years</li> <li>Taking verapamil</li> </ul>	Five days of treatment dose LMWH followed by 110mg BD
	<ul style="list-style-type: none"> <li>Age 75-80 years</li> <li>Moderate renal impairment</li> <li>Gastritis, oesophagitis or gastro-oesophageal reflux</li> <li>Increased risk of bleeding</li> </ul>	Five days of treatment dose LMWH followed by considering dose reduced dabigatran of 110mg BD
	CrCl<30mls/min	Contra-indicated
Apixaban	Standard dose (no dose adjustment required)	10mg BD for 7 days then 5mg BD  Use with caution in CrCl 15-29mL/min
	CrCl<15mls/min	Contra-indicated
Edoxaban	Standard dose	60mg OD
	Any of the following: <ul style="list-style-type: none"> <li>CrCl 15-50mls/min</li> <li>Weight &lt;60kg</li> <li>Use of ciclosporin, dronedarone, erythromycin or ketoconazole</li> </ul>	30mg OD
	CrCl<15mls/min	Contra-indicated
Rivaroxaban	Standard dose (no dose adjustment required)	15mg BD for 21 days then 20mg OD
	CrCl 15-49mls/min	15mg BD for 21 days then 15mg OD
	CrCl <15mls/min	Contra-indicated

Table 5: Table showing doses of DOACs for DVT/PE. Anticoagulation must be continued for a minimum of 3 months in this indication

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

## Management of patients on oral anticoagulants going for procedures which require interruption of anticoagulation

### Elective procedures

Refer to Trust Guideline: Peri-operative oral anticoagulant bridging. WAHT-KD-017 and <https://periop-handbook.ukclinicalpharmacy.org>



Peri-operative oral  
anticoagulant bridg

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

**Urgent procedures**

**High risk of thrombosis**


Patients with artificial heart valves should be discussed with Cardiology

Patient who have had a recent thrombosis (within the last 6 weeks) or have a target INR>2.5 should be discussed with Clinical Haematology.

**Low risk of thrombosis**

This is for patients with atrial fibrillation or distant thrombosis (more than 6 weeks ago)

**Warfarin**



- Prothrombin Complex Concentrate (PCC), currently Beriplex, is a factor concentrate of II, VII, IX and X. It rapidly reversed warfarin but comes with a significant risk of thrombosis (20%). The patient's weight and INR is required for dosing.
- Patient who attend hospital and may need theatre should be given iv vitamin K as soon as possible as this may prevent the need for PCC if they require an operation later in their hospital stay.
- When haemostasis is secure start prophylactic LMWH. Restart warfarin at usual dose when eating and no epidural. Continue LMWH until INR therapeutic for 2 days. Can be discharged on LMWH.

## WAHT-HAE-002

It is the responsibility of every individual to check that this is the latest version/copy of this document

### DOACs – Dabigatran, Apixaban, Edoxaban or Rivaroxaban

Dabigatran can be reversed with idarucizumab – details below.

Apixaban and rivaroxaban can be reversed with andexanet alfa – please refer to WAHT-HAE-037



Use of Andexanet  
Alfa for Reversing A

### Dabigatran

Check patient's CrCl:

- CrCl >80mls/min
  - Last dose >24 hours ago – proceed as normal, consider Idarucizumab\* if major bleeding
  - Last dose <24 hours ago
    - Operation can wait until >24 hours after last dose – after 24 hours proceed as normal, consider Idarucizumab\* if major bleeding
    - Operation cannot wait<sup>‡</sup> until >24 hours after last dose – give 5g Idarucizumab\*
- CrCl = 50-80mls/min
  - Last dose >48 hours ago – proceed as normal, consider Idarucizumab\* if major bleeding
  - Last dose <48 hours ago
    - Operation can wait until >48 hours after last dose – after 48 hours proceed as normal, consider Idarucizumab\* if major bleeding
    - Operation cannot wait<sup>‡</sup> until >48 hours after last dose – give 5g Idarucizumab\*
- CrCl <30mls/min
  - Last dose >72 hours ago – proceed as normal, consider Idarucizumab\* if major bleeding
  - Last dose <72 hours ago
    - Operation can wait until >72 hours after last dose – after 72 hours proceed as normal, consider Idarucizumab\* if major bleeding
    - Operation cannot wait<sup>‡</sup> until >72 hours after last dose – give 5g Idarucizumab\*

\*Idarucizumab is available from both the Alex and WRH Emergency Drug Cupboards after discussion with a Consultant Haematologist.

It is given as a 5g infusion over 10 minutes.


A second dose should be considered if there is evidence of a significant bleed (with prolonged clotting times), potential for another life threatening bleed or need for another urgent procedure.

Dabigatran can be restarted 24 hours after administration of idarucizumab if patient is clinically stable and adequate haemostasis has been achieved.

<sup>‡</sup>The decision on when the patient requires surgery, and therefore whether Idarucizumab is required, should only be made by the Consultant Surgeon.

<b>Oral Anticoagulants – Guidelines and Procedures</b>		
<b>WAHT-HAE-002</b>	Page 21 of 55	<b>Version 9</b>

## Management of patients on oral anticoagulants who are bleeding



### High risk of thrombosis

Patients with artificial heart valves should be discussed with Cardiology

Patient who have had a recent thrombosis (within the last 6 weeks) or have a target INR > 2.5 should be discussed with Clinical Hematology.


### Low risk of thrombosis

This is patients with atrial fibrillation or distant thrombosis (more than 6 weeks ago)

**WAHT-HAE-002**


It is the responsibility of every individual to check that this is the latest version/copy of this document

**Warfarin**



When haemostasis is secure consider prophylactic LMWH. Re-assess patient whether warfarin is beneficial. If re-starting warfarin restart warfarin at usual dose when eating and no epidural. Continue LMWH until INR therapeutic for 2 days. Can be discharged on LMWH.

**DOACs**



When haemostasis is secure consider prophylactic LMWH. Re-assess patient whether DOAC is beneficial. If re-starting DOAC restart at usual dose when eating and no epidural and >12 hours from last dose of LMWH

## **Overdosage of oral anticoagulants (no bleeding)**

### **Warfarin**

INR:

- >8.0 – give 1mg oral vitamin K and repeat following day
- <8.0 – withhold warfarin until INR within normal range (daily INRs)
- Treat bleeding as above

### **DOACs**

#### **Dabigatran**

- Withhold further doses
- Consider activated charcoal if ingestion in last 3 hours
- Consider Idarucizumab if significant overdosage (>6 tablets in 24 hours or CrCl <15mls/min)
- Treat bleeding as above

#### **Apixaban or Rivaroxaban**

- Withhold further doses
- Consider activated charcoal if ingestion in last 3 hours
- Consider administration of andexanet alfa if in line with indication
- Treat bleeding as above

#### **Edoxaban**

- Withhold further doses
- Consider activated charcoal if ingestion in last 3 hours
- Treat bleeding as above

\*Full details can be found on each drugs monograph on TOXBASE and further details on SPC of each medication.



**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

**Management of low INRs**

**Atrial fibrillation**

Increase dose of warfarin as necessary, no requirement for alternative anticoagulation.

**Mechanical heart valves**

Refer to the ESC guidelines 2012 for target INR range based on valve type and patient factors – image shown below: (European Heart Journal 2012;33:2451-2496 or <http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/valvular-heart-disease.aspx>)

**Table 20 Target international normalized ratio (INR) for mechanical prostheses**

Prosthesis thrombogenicity <sup>a</sup>	Patient-related risk factors <sup>b</sup>	
	No risk factor	Risk factor ≥1
Low	2.5	3.0
Medium	3.0	3.5
High	3.5	4.0

<sup>a</sup>Prosthesis thrombogenicity: Low = Carbomedics, Medtronic Hall, St Jude Medical, ON-X; Medium = other bileaflet valves; High = Lillehei-Kaster, Omniscience, Starr-Edwards, Bjork-Shiley and other tilting-disc valves.

<sup>b</sup>Patient-related risk factors: mitral or tricuspid valve replacement; previous thromboembolism; atrial fibrillation; mitral stenosis of any degree; left ventricular ejection fraction < 35%.

*Figure 1: Image showing target INR for mechanical prostheses as per European Heart Journal*

**Management of a Sub-Therapeutic INR during Routine Monitoring**

- If the INR is below the recommended range but 2.0 or more (e.g. target INR 3.0, range 2.5 – 3.5), increase warfarin dose and repeat INR weekly until in range
- If the INR is <2.0 but >1.6 (i.e. 1.7/1.8/1.9), administer low molecular weight heparin (e.g. enoxaparin 1mg/kg BD), increase the warfarin dose and repeat INR every 48-72 hours until >2.0
- If the INR is 1.6 or less, administer low molecular weight heparin immediately (e.g. enoxaparin 1mg/kg BD), but also consider discussing with cardiology urgently, particularly if mechanical valve is mitral, as IV unfractionated heparin may be preferred
- If CrCl<30mls/min and heparin is required, administer a single dose of enoxaparin 1mg/kg and discuss patient with cardiology as IV unfractionated heparin may be required
- Consider patient factors if INR control is poor (adherence to prescribed therapy, illness, interacting drug therapy, lifestyle factors including diet and alcohol, cognitive function)
- Other anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) **CANNOT** be used in place of warfarin for anticoagulation with mechanical heart valves.

**If patient is unwell with new heart failure or chest pain, please contact cardiology consultant or registrar urgently via Worcestershire Royal Hospital switchboard**

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

**Treatment of DVT/PE**

- Recent thrombosis (previous 6 weeks) with sub-therapeutic INR
  - INR 1.6-2.0 – increase dose of warfarin, recheck INR next day and give treatment dose LMWH (enoxaparin 1mg/kg BD) if still <2.0 until INR >2.0
  - INR <1.6 – increase dose of warfarin, give treatment dose LMWH (enoxaparin 1mg/kg BD) until INR >2.0
- Distant thrombosis (more than 6 weeks previously) with sub-therapeutic INR
  - INR 1.6-2.0 – increase dose of warfarin, recheck INR after 48 hours and give treatment dose LMWH if still <2.0 until INR >2.0
  - INR <1.6 – increase dose of warfarin, recheck INR after 24 hours and give treatment dose LMWH if still <2.0 until INR >2.0

Patients who have previously had a recurrent thrombosis with a sub-therapeutic INR should be started on therapeutic LMWH (enoxaparin 1mg/kg BD) whenever the INR is lower than the normal range.

## Inpatient warfarin management

### Prescription charts

All VKAs should be prescribed on the designated WAHT 'Adult Oral Anticoagulant Chart & Discharge Referral' WR1779 Version 5, called 'oral anticoagulant chart' in this document. All the required information should be entered for each patient. The chart is designed for warfarin prescribing, if acenocoumarol or phenindione is used then this should be written clearly on the chart. It should also be recorded on the patient's main drug chart that they are on a VKA and that the oral anticoagulant chart is also in use.

### Initiation of Warfarin

Before initiation of warfarin the patient should be fully counselled over the risks and benefits of warfarin, family members/carers may also be involved. This discussion along with the indication, target INR and intended duration should be documented in the notes and on the anticoagulant chart. Warfarin requires a loading dose which is higher than the normal maintenance dose, it is during the initiation of warfarin that there is the highest risk of a high INR and therefore bleeding complications. There are three initiation regimens:

1. Standard dose induction, this aims to achieve a therapeutic INR within 3-4 days and is used to reduce the time that the patient is on alternative anticoagulants, e.g. heparin, following the diagnosis of a thrombosis.
2. Low dose induction, this is for patients that require a therapeutic INR within 3-4 days but are at a higher risk of bleeding.
3. Very low dose induction, this is for patients usually in the community who require warfarin for AF without evidence of thrombosis. The patient receives 1mg for a week then has an INR check and the dose is increased by 1mg/week until the INR is therapeutic. The advantage to this regimen is the lower frequency of INR checks and the low probability of a high INR.

The first two regimens tend to be used in hospital. When commencing a patient on warfarin it is important to determine if the patient requires a standard or low dose induction. Risk factors requiring a low dose regimen are listed at the front of the oral anticoagulant chart. If a patient has one of these factors then the low dose regimen should be used. The person prescribing the warfarin must tick if a risk factor is present and sign that either the low or standard induction regimen is to be used.

Once it is determined which regimen is to be used then that days INR and warfarin dose must be entered in the chart, this is then signed for. The nurse administering the warfarin should only administer the warfarin if the chart is properly completed. For the first four days there must be a daily INR performed and recorded on the chart. Dosing is dependent on the INR and suggested doses are recorded on the chart. Warfarin should not be administered without a daily INR.

It might be prudent to start warfarin at the start of a week, maintaining them on low molecular weight heparin (LMWH) if there is a thrombosis, if the patient is going home to prevent problems with INR checks over the weekend.

Alternative anticoagulation given when there is a thrombosis, usually LMWH, needs to continue for at least five days and until the INR is therapeutic for 2 days, this is due to the initial pro-coagulant activity of warfarin. Consideration should be given to the re-introduction

<b>Oral Anticoagulants – Guidelines and Procedures</b>		
<b>WAHT-HAE-002</b>	Page 27 of 55	<b>Version 9</b>

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

of alternative anticoagulation if the INR falls below the desired therapeutic range in the first 4 weeks of treatment for a thrombosis or if there is a prolonged period (>3 days) when the INR is sub therapeutic.

**Warfarin maintenance**

The important factor when managing long-term warfarin is to make only minor changes to the dose to avoid large variations in the INR, suggestions are:

- Not to worry about one off readings slightly outside the normal range (e.g 1.8 or 3.6)
- Trends are more important than one off readings
- Small daily doses of warfarin require small adjustments, adjust total weekly dose rather than daily dose.

When a patient is admitted on warfarin page 2 of the oral anticoagulant chart needs to be completed. Information on pre-admission dose, target INR, indication and intended duration needs recording on the chart and in the medical notes. An INR must be recorded on admission and no warfarin should be prescribed or administered without an INR. For each day the prescriber must write the dose and the INR, where the INR is not required an 'X' must be put in the box and this signed for. The nurse administering the warfarin must sign and note the time of the dose, warfarin shouldn't be administered without either an INR or an 'X' in the box.

Hospital in-patient monitoring requirements are higher than outpatients as illness, drugs and changes in diet may affect the INR, suggested monitoring schedule is:

1. Daily INR for very ill patients, those started on antibiotics, those with liver dysfunction and those who have had drugs started or stopped which are known to interact with warfarin (see Appendix 1 'Interactions' of the British National Formulary, further information can also be sought from Medicines Information on 01473704431).
2. Every third day INR for patients not discussed in 1.
3. Outpatient style monitoring is suitable for long-term rehabilitation patients.

Suggested dose changes for a target INR of 2.5:

INR	<1.5	1.5-1.9	2.0-3.0	3.1-3.9	4.0-5.0
Dose adjustment (weekly)	Increase by 20%	Increase by 10%	No change	Decrease by 10%	Decrease by 20%

**Drugs interacting with warfarin**

Prescribers and pharmacists must check the potential interaction of any medicine that is to be prescribed concomitantly with oral anticoagulants - see the latest edition of the BNF Appendix 1: Interactions or call the local Medicines Information Centre (01473704431). Patients must be told to check any new or existing non-prescription medicines with the pharmacist or with a doctor if they are unsure. It usually takes between five to seven days for the drug to effect the INR.

In patients who are stabilised on warfarin and whose INR is within the target range on oral anticoagulants, control can be disrupted by:

- Initiating a new medicine which potentiates or inhibits the oral anticoagulant effect.

- Stopping an interacting medicine, the effect of which has already been compensated for through dose adjustment with the oral anticoagulant.

**For short courses (up to 5 days) of a new medicine**, oral anticoagulant dose adjustment is not usually necessary but the dose of warfarin should be reduced or omitted over this timescale if a strongly potentiating medicine is prescribed.

**For longer courses of treatment**, some initial alteration to the anticoagulant dose should be considered (especially if the INR is towards or at the upper limit) but in all cases, INR must be checked regularly after starting the new medicine and the oral anticoagulant dose adjusted accordingly. When the new medicine is stopped, a return to the previous maintenance dose may be needed.

**Antibiotics** – antibiotics may alter the gut flora changing the amount of vitamin K absorbed by the gut, therefore altering the INR. Patients starting antibiotics should have their INR more closely monitored.

**Alcohol** - in regular amounts alcohol acts as a hepatic enzyme inducer and can result in an increase in the maintenance oral anticoagulant dose. However, pulsed alcohol excess can potentiate the anticoagulant effect in a dose-dependent way. Patients should be warned to drink only in moderation, to avoid binge drinking and to be reasonably consistent in their alcohol consumption. Variable alcohol intake is one of the commonest reasons for poor anticoagulant control.

**Diet** - Major changes in diet (especially involving salads and vegetables) may affect warfarin control. Cranberry juice should be avoided. Refer to booklet/GP for further information on diet and lifestyle changes.

## Discharge arrangements

Inadequate follow-up arrangements are a major cause of VKA incidents. When a patient is discharged on VKAs it is the duty of the discharging doctor to ensure that the patient, GP and anticoagulant clinic are fully informed of the follow-up arrangement for INR testing. The patient must be discharged with their warfarin book completed and the trust patient information leaflet 'Anticoagulation Therapy Monitoring'. It is important if the patient is on drugs that potentially interact with warfarin that this information is passed onto the clinic taking over the warfarin dosing. Page 3 of the oral anticoagulation chart must be completed. There are three scenarios for discharge:

1. Patient newly started on warfarin. Initial follow-up is with the hospital for all patients. A follow-up appointment must be arranged by phoning ext 30863/30722. If the patient is discharged over the weekend this can be done on Monday morning, but it is unlikely there will be space for a clinic appointment that day so alternative arrangements may have to be made. Once follow-up arrangement has been made then page 3 of the anticoagulation chart must be completed in full and pages 1 to 3 emailed to the anticoagulant clinic at [wah-tr.anticoagulation@nhs.net](mailto:wah-tr.anticoagulation@nhs.net)
2. Patient established on warfarin normally attending the hospital anticoagulant clinic, same arrangements as above.
3. Patient established on warfarin normally managed by the GP. An appointment must be made for follow-up by the GP anticoagulant clinic. Page 3 of the anticoagulant chart must then be completed and pages 1-3 emailed to the GP practice. If the GP practice is unwilling to take the patient back they must be referred to the hospital INR clinic.

Oral Anticoagulants – Guidelines and Procedures		
WAHT-HAE-002	Page 29 of 55	Version 9

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

Pharmacy will not dispense warfarin without pages 1 to 3 of the anticoagulant chart being correctly completed. Patients in whom there has been a recent dose change or have had drugs that interact with warfarin started or stopped must have arrangements for a INR check in the first 3 days of discharge, this may mean them returning to the hospital for the INR check. Patients felt safe to be discharged with an INR greater than 4 should have an INR performed the following day.

**Information for Patients**

All patients discharged from hospital who are newly started on oral anticoagulants should be given:

- The yellow BSH/NPSA 'Oral Anticoagulant Therapy Record Book', completed with their recent INR results and doses.
- A copy of the Trust Anticoagulant Service Information leaflet for patients.
- A supply of 1mg and 3mg warfarin tablets (or appropriate phenindione tablets if this is used), depending on the patient's dose
- Verbal instructions about oral anticoagulant therapy.
- An appointment to have the next anticoagulant test / dose on an appropriate day.

All patients who are discharged on warfarin (new or old patients) should be given a copy of their inpatient anticoagulant chart to take home.

## Part 2 – In-Patient Anticoagulation With Oral Anticoagulants In WHAT -Responsibilities Of Each Profession

The Trust Oral Anticoagulant Guideline and Procedures is available on the Intranet and contains all the clinical information needed to prescribe oral anticoagulants safely and effectively. However there are still many occasions where this does not happen. It has been suggested that defining the responsibilities of each profession in managing oral anticoagulants would help to address the difficulties in the practical implementation of the guideline, and thereby improve the safety of warfarin prescribing within the Trust. This document defines all the tasks required by the MDT to ensure that anticoagulation treatment with warfarin is safe and appropriate to individual patient need. The overall responsibility for ensure each defined task is completed is identified to provide role definition and further enhance patient safety.

Task	Responsibility Of
<b>Newly initiated patients</b>	
<b>Pre-Treatment</b>	
Decision to initiate oral anticoagulant	AUTHORISED PRESCRIBER
Discussion of risks/benefits with patient and obtaining patient consent	AUTHORISED PRESCRIBER
Decision on: <ul style="list-style-type: none"> <li>• Target INR</li> <li>• Duration of treatment</li> <li>• Frequency of INR testing</li> </ul>	AUTHORISED PRESCRIBER
Documentation of all of above in notes and relevant section on oral anticoagulant prescription chart	AUTHORISED PRESCRIBER

<b>ALL PATIENTS (NEW AND ESTABLISHED)</b>	
<b>Prescribing</b>	
Organisation of baseline bloods and INR	AUTHORISED PRESCRIBER*
Documentation of baseline bloods and INR	AUTHORISED PRESCRIBER*
Annotation made on in-patient drug chart to indicate patient on oral anticoagulant as per Trust Medicines Policy	AUTHORISED PRESCRIBER*

Request card completed for INR to be taken the next morning or where INR result not required that day, INR box crossed through on oral anticoagulant prescription chart	AUTHORISED PRESCRIBER*
Nurse looking after patient informed of decision to treat and arrangements for blood test communicated	AUTHORISED PRESCRIBER*
Check that blood for INR taken by 10am daily	NURSE **
Where no phlebotomy service or generic worker available, to ensure blood taken by 10am, refer back to prescriber	NURSE
INR written in the chart and dose prescribed on oral anticoagulant chart by 6pm that day in line with Trust dosing guidance	AUTHORISED PRESCRIBER*
<b>Pre-administration checks</b>	
INR documented on drug chart or INR box crossed through (indicating INR result not due that day) and days dose signed for.	NURSE
<p>Appropriateness of prescribed dose to be administered evaluated against documented INR and guideline dosing advice</p> <p>Where doubt as to:</p> <ul style="list-style-type: none"> <li>• appropriateness of dose</li> <li>• impact of interacting concurrent medicines by checking relevant section on chart or where not known discussion with pharmacist</li> <li>• change to clinical condition exists, <b>referral</b> to prescriber or clinical pharmacist made (on-call pharmacist out of hours).</li> </ul>	NURSE
<p>Checking oral anticoagulant prescription is prescribed according to oral anticoagulant guideline:</p> <ul style="list-style-type: none"> <li>• Appropriateness of dose</li> <li>• Concurrent medication evaluated for potential interaction with oral anticoagulant, clinical significance evaluated and details documented on oral anticoagulant chart and appropriate paperwork</li> <li>• Administration guidance to nursing staff pro-actively and as requested</li> </ul> <p><b>Where dose change required</b>, prescriber <b>verbally</b> contacted, clinical decision made and agreed adjustments documented on oral anticoagulant prescription chart and associated paperwork according to guideline and communicated to the responsible nurse</p>	PHARMACIST
<b>Administration</b>	
Dose administered and administration details documented on oral anticoagulant prescription chart	NURSE



In the event of a non-administration, <ul style="list-style-type: none"> <li>• appropriate coding, documentation and notification of the non-administration made to the prescriber</li> <li>• Clinical impact evaluated and alternative plan defined and undertaken</li> </ul>	NURSE  AUTHORISED PRESCRIBER
<b>Discharge</b>	
<b>1. Anticoagulation clinic-managed oral anticoagulant treatment</b> (including ALL newly initiated patients)	
Completing discharge prescription and referral paperwork	AUTHORISED PRESCRIBER*
Documenting indication, target INR, required frequency of testing, dose definition for discharge and any other clinically significant information on appropriate paperwork <b>AND the patient-held record (OAT PACK)</b> <sup>1</sup>	AUTHORISED PRESCRIBER*
Supplying an appropriate quantity of oral anticoagulant in appropriate strengths seeking to minimise risk of patient confusion and enhance concordance	PHARMACIST
Ensuring patient has had supplementary counselling on oral anticoagulant therapy and the opportunity to ask questions if needed	PHARMACIST/ NURSE
Arranging appointment with clinic, sending referral form and copy of in-patient chart to clinic	NURSE/WARD CLERK***
<b>2. GP-managed oral anticoagulant treatment</b>	
Contact made with GP and agreement to take over oral anticoagulant management made	AUTHORISED PRESCRIBER*
Arrangements in place with GP surgery on when blood monitoring to be next undertaken (date to be specified) after discharge and communication of this to patient/carer/relative/nursing home as appropriate	AUTHORISED PRESCRIBER*
Discharge prescription and referral paperwork completed in a timely manner appropriate to discharge date and time	AUTHORISED PRESCRIBER*
Indication, target INR, required frequency of testing, initial dose definition and any other clinically significant information documented on appropriate paperwork and patient-held record	AUTHORISED PRESCRIBER*

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

---

<sup>1</sup> Oral Anticoagulation Therapy Pack (contains the OAT Record Book, the OAT Important Information for Patients Booklet, the OAT Important Information for Dental Patients Leaflet, and an Anticoagulant Alert card).  
OAT Packs are to be supplied from Ward or Clinic stocks

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

Appropriate quantity of oral anticoagulant in appropriate strengths supplied (to minimise risk of patient confusion over dose).	PHARMACIST
Ensuring patient has had supplementary counselling on oral anticoagulant therapy and the opportunity to ask questions as needed	PHARMACIST/ NURSE

**Notes:**

- \* Where Trust approved local arrangement exists as appropriate Advanced Nurse Practitioner role
- \*\*This should be done by phlebotomist or generic worker whenever possible but it remains the overall responsibility of the nurse to ensure happens.
- \*\*\*Where local agreement exists this may be done by ward clerk but proper arrangements must be in place to ensure this happens if ward clerk not available/present that day or outside of their hours

**Procedures/Competences**

*The following documents are adapted from the work competences published by the NPSA to include local detail as described in the Trust 'Oral Anticoagulant Guideline and Procedures'. The content should be used by the appropriate professional groups when assessing the competences of staff to initiate, monitor, dispense, administer and discharge patients on warfarin, within their own individual professional competency assessment framework.*

**Initiating oral anticoagulant therapy – Authorised Prescribers**

*Some aspects (excluding prescribing) also undertaken by Anticoagulant Nurses and Advanced Nurse Practitioners*

<ol style="list-style-type: none"> <li><b>1. Ensure you are familiar with the Trust Guidelines and Procedures on ORAL ANTICOAGULANTS WAHT-HAE-002.</b> Read the patient's notes and prescription, and identify any special instructions, investigations (including abnormal blood test results), or issues for which you need to seek advice.</li> <li><b>2.</b> Assess the appropriateness and risks of the intended treatment against the patient's diagnosis, current health and social status, medication, allergy status, other treatment and the patient's preferences.</li> <li><b>3.</b> Determine the appropriate loading dose regimen for the patient, which medicines to prescribe, the dosage, the frequency of administration, and the most effective route of administration.</li> <li><b>4. Decide who will monitor and dose the anticoagulants</b> and what day would be the safest time to start treatment (see loading dose schedule), bearing in mind the need for daily INR monitoring for the first 4-5 days. If there is any doubt it is safest to start warfarin on a Sunday, Monday or Tuesday, giving extra days of therapeutic dose enoxaparin if necessary until the INR is within therapeutic range</li> <li><b>5.</b> Document the indication for use, target INR, duration of treatment and monitoring plan in the patient's notes. If uncertain, set a review date, which should be at least annual.</li> <li><b>6.</b> Order and document baseline INR, APTT ratio and platelet count blood tests prior to the administration of the first dose of anticoagulant. Check liver function if</li> </ol>	
--	--

in any doubt about this. Abnormal results may influence the decision to anticoagulate. Consider haemophilia screening if appropriate (see Appendix 1)

7. Ensure that the patient receives verbal and written information concerning their anticoagulant therapy prior to the first dose of anticoagulant, using the yellow BSH/NPSA Oral Anticoagulant Therapy Important Information for Patients pack (including Record Book and Anticoagulation Alert Card) In addition, give the Trust Anticoagulation Service leaflet explaining local arrangements for anticoagulation dosing and monitoring. If patient to be transferred to GP dosing then it needs to be explained that GP service may be different.

8. Prescribe the anticoagulant treatment according to the Medicines Policy and the Trust Oral Anticoagulant Guidelines and Procedures and before 6pm daily to ensure safe and optimal delivery of treatment

9. Prescribe the warfarin on the main prescription chart in the Regular Medicines section, but write across the administration boxes ' see separate chart' and then complete the separate Trust warfarin prescription chart, including:

- indication and target INR
- the approved name of anticoagulant medicine(s);
- dose, route and frequency of administration;
- monitoring plan

10. Prescribe legibly, ensuring your intention for treatment and monitoring is clear, accurate and complete and that there are no ambiguities.

11. Inform/ discuss with the nurse looking after the patient of the decision to treat and the arrangements for the blood tests

12. Review the anticoagulant prescription in accordance with the monitoring plan. When there have been two consecutive INR results within the therapeutic range, the frequency of testing may be reduced to every 3 days providing that the clinical situation remains stable and no interacting medicines have been prescribed. **If the INR is not to be measured put a cross in the INR box for that day, otherwise it will be queried and/or the patient may not receive their dose.**

13. Modify any subsequent prescriptions in accordance with national and local guidelines and in light of the laboratory test results, side effects, complications and response to treatment. If any doses have not been administered as prescribed, take account of this and seek advice where necessary.

14. Recognise when you need help and seek advice and support from an appropriate source when the needs of the individual and the complexity of the case are beyond your competence and capability.

15. When transferring the care of the patient to another healthcare team and especially on discharge from hospital, ensure that the new team is sent information concerning the clinical indication for use, target INR, intended duration of therapy, current prescription and recent laboratory test results.

16. Arrange for the patient to receive an initial supply of warfarin along with clear instructions of how to make up the dose and when to take it.

**MAINTAINING ORAL ANTICOAGULANT THERAPY**

**You need to:**

1. Read the patient's notes, previous prescription and protocol, and identify any special instructions. Review the results of all relevant investigations (including blood test results) and identify any issues on which you need to seek advice.
2. Greet, accurately identify the patient and introduce yourself and any colleagues present to the patient and/or carer.
3. If a carer is present, ensure that the patient consents to their presence throughout the assessment and is willing for them to receive the same information as that given to the patient.
4. Undertake and document measurement of the INR in accordance with national and local guidelines.
5. Review the patient's history since their last attendance.
6. Following agreed protocols and/or care pathways, explain the treatment alternatives and their risks and benefits to the patient and/or carer together with any potential side effects and their management, and accurately answer any questions at a pace and level that is appropriate to:
  - their emotional state;
  - their level of understanding;
  - their culture and background;
  - their preferred ways of communicating;
  - their needs.
7. Explain any lifestyle changes that will be needed in order to ensure good anticoagulant control.
8. Check that the patient and/or carer understand the treatment choices being offered, the implications of this choice and any potential side effects together with their management.
9. Ensure that the patient receives verbal and written information concerning the way in which their anticoagulant therapy is to be continued.
10. Update the patient-held record of anticoagulant treatment in response to the patient's INR using local guidelines and decision support software e.g. DAWN
11. Inform the patient and their GP about the outcome of the assessment, in accordance with local policy. If the patient has a high or low INR take appropriate action, following the clinical guideline and local procedures.
12. Record and report your findings, recommendations, patient and/or carer's response and issues to be addressed according to local guidelines.
13. Recognise when you need help and seek advice and support from an appropriate source when the needs of the individual and the complexity of the case are beyond your competence and capability.
14. When transferring the care of the patient to another healthcare team and especially on discharge from hospital, ensure that the new team is sent information concerning the clinical indication for use, target INR, intended duration of therapy, current prescription and recent laboratory test results.

## **DISPENSING ORAL ANTICOAGULANTS**

**Please note Pharmacy staff should follow the more detailed departmental SOP and associated competency documents.**

**You need to:**

1. Find out what the patient already understands and remembers.
2. Ensure that the patient has been issued with appropriate information (e.g. yellow book), and has had the contents fully explained to them
3. Ensure that arrangements are in place for INR monitoring and follow-up, and that the patient and/or carer understand these. In particular, that the patient knows if they have to wait for a phone-call from the GP/clinic before taking their dose.
4. Check that the INR level is safe before issuing or dispensing repeat prescriptions for oral anticoagulants. Check if the patient is prescribed any interacting medicines and if so make arrangements for additional INR blood tests, and to inform the anticoagulant service that an interacting medicine has been prescribed.
5. Accurately answer any questions relating to the patient's therapy at a pace and level that is appropriate to:
  - their emotional state;
  - their level of understanding;
  - their culture and background;
  - their preferred ways of communicating;
  - their needs.
6. Explain in clear and simple terms what the medicines are for and when the patient needs to take them.
7. Explain any lifestyle changes that will be needed in order to ensure good anticoagulant control.
8. Check that the patient and/or carer understand the prescribed treatment and the lifestyle implications of that treatment.
9. Ensure that the patient and/or carer understands how to take the correct dose in relation to the number of milligrams and the number of tablets to be taken.
10. Ensure the medicines are dispensed with written instructions (e.g. patient information leaflet) on what they are for, how and when to take them, the date dispensed and the expiry date.
11. Explain the importance of remembering to take every dose prescribed.
12. Inform the patient of side effects or symptoms the medicines may produce, how common or rare these are, how to recognise them and what action to take.
13. Ensure the patient is aware of the potential for anticoagulants to interact with other medicines, including those bought over-the-counter, and that they understand the need to consult with a pharmacist or the prescriber before taking other medicines.
14. Offer compliance aids, if appropriate, to help the patient to remember to take every dose prescribed. However, a risk assessment should be undertaken

<p>on the use of Monitored Dosage Systems for anticoagulants for individual patients. The general use of Monitored Dosage Systems for anticoagulants should be minimised as dosage changes using these systems are more difficult.</p>	
--	--

### **ADMINISTERING (AND DISCHARGING PATIENTS ON) ORAL ANTICOAGULANTS**

#### **Administration to in-patients**

##### **You need to:**

1. If INR test ordered, check that the blood for INR has been taken by 10am daily, if not take blood or refer back to prescriber
2. Document the INR result on the warfarin prescription chart by the end of the early shift 4pm each day, or if not possible to obtain result hand over to late shift
3. Evaluate the appropriateness of the prescribed dose against the documented INR. Consider the Trust Guideline dosing advice/prescription chart, any interacting medicines or change to patient's clinical condition. If in doubt refer to prescriber or clinical pharmacist (on-call out of hours)
4. Accurately answer any questions relating to the patient's therapy at a pace and level that is appropriate to:
  - their emotional state;
  - their level of understanding;
  - their culture and background;
  - their preferred ways of communicating;
  - their needs.
5. Explain in clear and simple terms what the medicines are for and when the patient needs to take them.
6. Explain any lifestyle changes that will be needed in order to ensure good anticoagulant control.
7. Check that the patient and/or carer understand the prescribed treatment and the lifestyle implications of that treatment.
8. Where the INR box is completed (either with a result or a cross indicating that an INR is not required), administer the prescribed dose and document on warfarin prescription chart
9. If the dose is not administered for whatever reason, document and inform the prescriber

#### **Discharge**

##### **You need to:**

1. Find out what the patient already understands and remembers.
2. Ensure that the patient has been issued with appropriate information (e.g. yellow book), and has had the contents fully explained to them
3. Ensure that arrangements are in place for INR monitoring and follow-up (date, time and location of new test) as per agreement with the commissioner (making appointments and sending referral form/copy of in-patient chart to GP/clinic may be delegated to the ward clerk), and that the patient and/or carer understand these. In particular, that the patient knows if they have to wait for a

<p>phone-call from the GP/clinic before taking their dose.</p> <ol style="list-style-type: none"> <li><b>4.</b> Ensure that the patient and/or carer understands how to take the correct dose in relation to the number of milligrams and the number of tablets to be taken.</li> <li><b>5.</b> Ensure the medicines are dispensed with written instructions (e.g. patient information leaflet) on what they are for, how and when to take them, the date dispensed and the expiry date.</li> <li><b>6.</b> Explain the importance of remembering to take every dose prescribed.</li> <li><b>7.</b> Inform the patient of side effects or symptoms the medicines may produce, how common or rare these are, how to recognise them and what action to take.</li> <li><b>8.</b> Ensure the patient is aware of the potential for anticoagulants to interact with other medicines, including those bought over-the-counter, and that they understand the need to consult with a pharmacist or the prescriber before taking other medicines.</li> <li><b>9.</b> Discuss with the pharmacist whether a compliance aid would be appropriate, to help the patient to remember to take every dose prescribed. However, a risk assessment should be undertaken on the use of Monitored Dosage Systems for anticoagulants for individual patients. The general use of Monitored Dosage Systems for anticoagulants should be minimised as dosage changes using these systems are more difficult.</li> </ol>	
--	--



## Appendix A - Conversion between the drugs

Starting drug	Convert to	Instructions
Warfarin	LMWH†	Stop warfarin, check INRs daily, start LMWH when INR sub-therapeutic (<2.0)
	Apixaban	Stop warfarin, check INRs daily, start apixaban when INR sub-therapeutic (<2.0)
	Dabigatran	Stop warfarin, check INRs daily, start dabigatran when INR sub-therapeutic (<2.0)
	Rivaroxaban	Stop warfarin, check INRs daily, start rivaroxaban when INR sub-therapeutic (<2.5)
	Edoxaban	Stop warfarin, check INRs daily, start edoxaban when INR <2.5
LMWH	Warfarin	Continue LMWH for at least 5 days and until INR has been therapeutic for 2 days then stop LMWH
	Apixaban	Stop LMWH, start apixaban 0-2 hours before next dose of LMWH would have been due
	Dabigatran	Stop LMWH, start dabigatran 0-2 hours before next dose of LMWH would have been due
	Rivaroxaban	Stop LMWH, start rivaroxaban 0-2 hours before next dose of LMWH would have been due
	Edoxaban	Stop LMWH, start edoxaban 0-2 hours before next dose of LMWH would have been due

Apixaban	LMWH	Stop apixaban, start LMWH 0-2 hours before next dose of apixaban would have been due
	Dabigatran	Stop apixaban, start dabigatran 0-2 hours before next dose of apixaban would have been due
	Rivaroxaban	Stop apixaban, start rivaroxaban 0-2 hours before next dose of apixaban would have been due
	Edoxaban	Stop apixaban, start edoxaban 0-2 hours before next dose of apixaban would have been due
	Warfarin*	Stop apixaban, start LMWH 0-2 hours before next dose of apixaban would have been due, start warfarin next day, continue LMWH for at least 5 days and until INR has been therapeutic for 2 days then stop LMWH
Dabigatran	LMWH	Stop dabigatran, start LMWH 0-2 hours before next dose of dabigatran would have been due
	Apixaban	Stop dabigatran, start apixaban 0-2 hours before next dose of dabigatran would have been due
	Rivaroxaban	Stop dabigatran, start rivaroxaban 0-2 hours before next dose of dabigatran would have been due
	Edoxaban	Stop dabigatran, start edoxaban 0-2 hours before next dose of dabigatran would have been due
	Warfarin*	Stop dabigatran, start LMWH 0-2 hours before next dose of dabigatran would have been due, start warfarin next day, continue LMWH for at

		least 5 days and until INR has been therapeutic for 2 days then stop LMWH
Rivaroxaban	LMWH	Stop rivaroxaban, start LMWH 0-2 hours before next dose of rivaroxaban would have been due
	Apixaban	Stop rivaroxaban, start apixaban 0-2 hours before next dose of rivaroxaban would have been due
	Dabigatran	Stop rivaroxaban, start dabigatran 0-2 hours before next dose of rivaroxaban would have been due
	Edoxaban	Stop rivaroxaban, start edoxaban 0-2 hours before next dose of rivaroxaban would have been due
	Warfarin*	Stop rivaroxaban, start LMWH 0-2 hours before next dose of rivaroxaban would have been due, start warfarin next day, continue LMWH for at least 5 days and until INR has been therapeutic for 2 days then stop LMWH
Edoxaban	LMWH	Stop edoxaban, start LMWH 0-2 hours before next dose of edoxaban would have been due
	Apixaban	Stop edoxaban, start apixaban 0-2 hours before next dose of edoxaban would have been due
	Dabigatran	Stop edoxaban, start dabigatran 0-2 hours before next dose of edoxaban would have been due
	Rivaroxaban	Stop edoxaban, start rivaroxaban 0-2 hours before next dose of edoxaban would have been due
	Warfarin*	Stop edoxaban, start LMWH 0-2 hours before next dose of edoxaban would have

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

		<p>been due, start warfarin next day, continue LMWH for at least 5 days and until INR has been therapeutic for 2 days then stop LMWH</p>
--	--	--

\*as the DOACs affect the INR it is difficult to determine the effect of the warfarin while also taking a DOAC therefore it is safer to convert to LMWH while introducing the warfarin.

†Low molecular weight heparin

## Appendix B – Atrial fibrillation risk calculators

### CHA<sub>2</sub>DS<sub>2</sub>-VASC Score

Risk factor		Score
Age	<65 years	0
	65-74 years	1
	≥75 years	2
Female sex		1
Congestive cardiac failure		1
Hypertension		1
Stroke/TIA/Thromboembolism		2
Vascular disease history		1
Diabetes history		1

Total Score	Yearly ischemic stroke (%) without anticoagulation	Yearly stroke, TIA or embolism risk (%) without anticoagulation
0	0.2	0.3
1	0.6	0.9
2	2.2	2.9
3	3.2	4.6
4	4.8	6.7
5	7.2	10.0
6	9.7	13.6
7	11.2	15.7
8	10.8	15.2
9	12.2	17.4

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

**ORBIT Bleeding risk score for AF**

Risk factor	Score
Male and Hb<13g/dL OR hematocrit <40% OR female and Hb<12g/dL OR hematocrit <36%	2
Age >74 years	1
Bleeding history (previous GI bleed, intracranial bleed or hemorrhagic stroke)	2
CrCl<60mls/min	1
Treatment with antiplatelet agents	1

Total Score	Risk group	Bleeds per 100 patient-years
0-2	Low	2.4
3	Medium	4.7
4-7	High	8.1

## CONTRIBUTION LIST

### Key individuals involved in developing the document

Name	Designation
Dr Davies	Consultant Haematologist
Keith Hinton	Clinical Team Lead Pharmacist, Surgery & Critical Care
Mohima Akhtar	Lead Pharmacist for Stroke & Thrombosis

### Circulated to the following Clinical Leads and individuals

Name	Designation
Dr Abban	Consultant Cardiologist
Oliver Chapman	Consultant Haematologist
Vivienne Pettit	Advanced Clinical Nurse Specialist Thrombosis
Peter James	Advanced Clinical Nurse Specialist haematology
Nick Pemberton	Consultant Haematologist
Thomas Skibbe	Consultant Haematologist
William Simmons	Consultant Haematologist
Khin Thein	Speciality Doctor Haematology
Juliet Mills	Consultant Haematologist
Paul Rajjayabun	DMD Surgery

## MONITORING TOOL

This should include realistic goals, timeframes and measurable outcomes.

How will monitoring be carried out?

Monitoring of Datix reports of non-compliance.

Routine pharmacy audit

Who will monitor compliance with the guideline?

Anticoagulation Safety Committee / Medicine Safety Committee

STANDARDS	%	CLINICAL EXCEPTIONS
Patients on warfarin must have a baseline/admission INR and then regular INR monitoring	100%	None
Any high INRs must be appropriately investigated and treated	100%	None

**Supporting Document 1 - Equality Impact Assessment Tool**

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval



**Herefordshire & Worcestershire STP - Equality Impact Assessment (EIA) Form**

**Please read EIA guidelines when completing this form**

**Section 1 - Name of Organisation** (please tick)

Herefordshire & Worcestershire STP	<input type="checkbox"/>	Herefordshire Council	<input type="checkbox"/>	Herefordshire CCG	<input type="checkbox"/>
Worcestershire Acute Hospitals NHS Trust	<input checked="" type="checkbox"/>	Worcestershire County Council	<input type="checkbox"/>	Worcestershire CCGs	<input type="checkbox"/>
Worcestershire Health and Care NHS Trust	<input type="checkbox"/>	Wye Valley NHS Trust	<input type="checkbox"/>	Other (please state)	<input type="checkbox"/>

<b>Name of Lead for Activity</b>	<b>Mohima Akhtar</b>
----------------------------------	----------------------

<b>Details of individuals</b>	
-------------------------------	--



<b>completing this assessment</b>	<b>Name</b>	<b>Job title</b>	<b>e-mail contact</b>
	Mohima Akhtar	Pharmacist	<a href="mailto:mohima.akhtar1@nhs.net">mohima.akhtar1@nhs.net</a>
<b>Date assessment completed</b>	<b>31/07/24</b>		

## Section 2

Activity being assessed (e.g. policy/procedure, document, service redesign, policy, strategy etc.)	<b>Title:</b>  <b>Guideline for warfarin and other oral anticoagulants</b>			
What is the aim, purpose and/or intended outcomes of this Activity?	Anticoagulants are one of the classes of medicines most frequently identified as causing preventable harm and admission to hospital. Managing the risks associated with anticoagulants can reduce the chance of patients being harmed.			
Who will be affected by the development & implementation of this activity?	<input checked="" type="checkbox"/>	Service User	<input checked="" type="checkbox"/>	Staff
	<input checked="" type="checkbox"/>	Patient	<input type="checkbox"/>	Communities
	<input type="checkbox"/>	Carers	<input type="checkbox"/>	Other _____
	<input type="checkbox"/>	Visitors	<input type="checkbox"/>	
Is this:	<input checked="" type="checkbox"/> Review of an existing activity <input type="checkbox"/> New activity <input type="checkbox"/> Planning to withdraw or reduce a service, activity or presence?			

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

<p>What information and evidence have you reviewed to help inform this assessment? (Please name sources, eg demographic information for patients / services / staff groups affected, complaints etc.</p>	<p>See reference list</p>
<p>Summary of engagement or consultation undertaken (e.g. who and how have you engaged with, or why do you believe this is not required)</p>	<p>Sent to key stakeholders for comments</p> <p>Approved by the Trust Thrombosis Committee on:</p> <p>Ratified by the Medicines Safety Committee on:</p>
<p>Summary of relevant findings</p>	

**Section 3**

Please consider the potential impact of this activity (during development & implementation) on each of the equality groups outlined below. **Please tick one or more impact box below for each Equality Group and explain your rationale.**

Please note it is possible for the potential impact to be both positive and negative within the same equality group and this should be recorded. Remember to consider the impact on e.g. staff, public, patients, carers etc. in these equality groups.

Equality Group	Potential <u>positive</u> impact	Potentia l <u>neutral</u> impact	Potential <u>negative</u> impact	Please explain your reasons for any potential positive, neutral or negative impact identified
Age		✓		
Disability		✓		

<b>Equality Group</b>	<b>Potential <u>positive</u> impact</b>	<b>Potential <u>neutral</u> impact</b>	<b>Potential <u>negative</u> impact</b>	<b>Please explain your reasons for any potential positive, neutral or negative impact identified</b>
<b>Gender Reassignment</b>		✓		
<b>Marriage &amp; Civil Partnerships</b>		✓		
<b>Pregnancy &amp; Maternity</b>		✓		
<b>Race including Traveling Communities</b>		✓		
<b>Religion &amp; Belief</b>		✓		
<b>Sex</b>		✓		
<b>Sexual Orientation</b>		✓		
<b>Other Vulnerable and</b>		✓		

**WAHT-HAE-002**

It is the responsibility of every individual to check that this is the latest version/copy of this document

<b>Equality Group</b>	<b>Potential <u>positive</u> impact</b>	<b>Potential <u>neutral</u> impact</b>	<b>Potential <u>negative</u> impact</b>	<b>Please explain your reasons for any potential positive, neutral or negative impact identified</b>
<b>Disadvantaged Groups</b> (e.g. carers; care leavers; homeless; Social/Economic deprivation, travelling communities etc.)		✓		
<b>Health Inequalities</b> (any preventable, unfair & unjust differences in health status between groups, populations or individuals that arise from the unequal distribution of social, environmental & economic conditions within societies)		✓		

**Section 4**

<b>What actions will you take to mitigate any potential negative impacts?</b>	<b>Risk identified</b>	<b>Actions required to reduce / eliminate negative impact</b>	<b>Who will lead on the action?</b>	<b>Timeframe</b>
	None	.		
<b>How will you monitor these actions?</b>				
<b>When will you review this EIA?</b> (e.g in a service redesign, this				

EIA should be revisited regularly throughout the design & implementation)	
---	--

**Section 5** - Please read and agree to the following Equality Statement

**1. Equality Statement**

1.1. All public bodies have a statutory duty under the Equality Act 2010 to set out arrangements to assess and consult on how their policies and functions impact on the 9 protected characteristics: Age; Disability; Gender Reassignment; Marriage & Civil Partnership; Pregnancy & Maternity; Race; Religion & Belief; Sex; Sexual Orientation

1.2. Our Organisations will challenge discrimination, promote equality, respect human rights, and aims to design and implement services, policies and measures that meet the diverse needs of our service, and population, ensuring that none are placed at a disadvantage over others.

1.3. All staff are expected to deliver services and provide services and care in a manner which respects the individuality of service users, patients, carer’s etc, and as such treat them and members of the workforce respectfully, paying due regard to the 9 protected characteristics.

<b>Signature of person completing EIA</b>	Mohima Akhtar
<b>Date signed</b>	31/07/2024
<b>Comments:</b>	
<b>Signature of person the Leader Person for this activity</b>	
<b>Date signed</b>	

**Comments:**



## Supporting Document 2 – Financial Impact Assessment

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

	<b>Title of document:</b>	<b>Yes/No</b>
1.	Does the implementation of this document require any additional Capital resources	No
2.	Does the implementation of this document require additional revenue	No
3.	Does the implementation of this document require additional manpower	No
4.	Does the implementation of this document release any manpower costs through a change in practice	No
5.	Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff	No
	Other comments:	

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval.